Anheuser-Busch Inbev SA (BUD) Stock Price Today
Aura AI Summary
Key Stats
- $166.59BMarket Cap
- 2,446,880Volume
- Consumer StaplesSector
- $86.4852W High
- $60.0152W Low
- 75 DaysTypical Hold Time
- $231.00BEnterprise Value
- 1.6%Div Yield
- -Trading Activity
Track Anheuser-Busch Inbev SA (BUD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Anheuser-Busch Inbev SA has traded between a low of $60.01 and a high of $86.48, highlighting its annual price range. Buy and sell Anheuser-Busch Inbev SA shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Most Recent News
Buckreef drives revenue to self-fund TRX Gold expansion amid strong gold market outlook.
TRX Gold Corporation is leveraging revenue from its Buckreef project to self-fund its expansion plans, reducing reliance on external financing. The gold market remains supportive with strong price forecasts for 2027 despite recent pullbacks. While th...

Trump administration launches new fraud-reporting commission program and reports progress on missing children and crime reduction.
In Week 92 of President Trump's second term, the administration introduced a 1% commission program rewarding Americans for reporting government fraud. They have located many missing unaccompanied alien children from previous years and reported signif...

Protagonist Therapeutics shifts to royalty model with FDA approvals and $300M buyback plan
Protagonist Therapeutics has transformed into a royalty-driven company with two FDA-approved drugs and strong cash reserves. The company secured lucrative royalties and milestones from partners Takeda and J&J, reducing its operational risks while mai...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.